RxDoctor Payments Data

George Ponce, MD

Cardiovascular Disease · Moreno Valley, CANPI 1174554935

Payments from drug & device makers

$14,188in general payments, 2019–2025

Across 414 payments — averaging $34.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Inari Medical, Inc.$2K
  • Bayer$674
  • Amarin Pharma, Inc.$664
  • Novartis$590
  • Merck$555
  • plus $5K from 36 others

What the payments were for

  • Consulting fees$1,82513%
  • Travel & lodging$2,06615%
  • Food & beverage$10,24272%
  • Education$170%
  • Other$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,188 in reported general payments places this provider in the 75th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$127,281
Medicare patients
738
Services billed
1,851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban205$177,831
EntrestoSacubitril/Valsartan170$162,533
JardianceEmpagliflozin101$88,597
OzempicSemaglutide53$54,140
XareltoRivaroxaban24$24,752
MultaqDronedarone Hcl23$23,804
JanuviaSitagliptin Phosphate14$15,356
BrilintaTicagrelor20$13,441
Repatha SureclickEvolocumab23$12,475
KerendiaFinerenone14$10,936
Ranolazine ErRanolazine64$4,052
Amiodarone Hcl110$2,437
Flecainide Acetate103$2,413
Metoprolol Succinate139$1,632
Rosuvastatin Calcium106$1,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$418$177,831205 claims
NovartisEntresto$590$162,533170 claims
Boehringer IngelheimJardiance$356$88,597101 claims
Novo NordiskOzempic$194$54,14053 claims
Johnson & JohnsonXarelto$306$24,75224 claims
MerckJanuvia$555$15,35614 claims
AstraZenecaBrilinta$133$13,44120 claims
BayerKerendia$674$10,93614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Moreno Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →